ArticleCells2026
Schwann Cell Activity in the Multiple Sclerosis Microenvironment.
Article in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Schwann cell (SC)-based therapy is currently being debated as an approach to promote functional recovery in patients with multiple sclerosis (MS) and other inflammatory demyelinating diseases of the central nervous system (CNS). The main limitation of SC transplantation in MS patients is the short-term functional activity of SCs in the CNS environment. The goal of this study was to determine phenotypic, functional, and signaling changes in human SCs treated with CSF samples from MS patients in vitro, and to characterize the molecular mechanisms underlying SC injury response in the model MS microenvironment. We demonstrated that SC proliferation and motility were suppressed, while the expression of both pro-myelinating genes and negative regulators of myelination was up-regulated in cells incubated with CSF from MS patients. This was associated with active phosphorylation of ERK and c-Jun, and inhibition of these signaling pathways prevented SC changes. The overall analysis of detected abnormalities and SC markers indicates that SCs do not exhibit either a 'classic' dedifferentiation-repair-like phenotype or a myelin-forming maturation phenotype when placed in MS-like conditions. They demonstrate an uncommon pattern of cellular signaling reprogramming, associated with decreased motility and potentially decreased myelination. We thus suggest that ERK- and JNK-modulated SCs should be further investigated as a potential cell source for CNS repair in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.